Lead Product(s): TOTUM-63
Therapeutic Area: Endocrinology
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Nestle Health Science
Deal Size: $67.1 million Upfront Cash: $5.1 million
Deal Type: Partnership February 05, 2020
Partnership secures funding for the development and commercialization of TOTUM-63. Agreement also includes TOTUM-63 supply to Nestlé Health Science.